Sarepta Therapeutics Inc (SRPT)

Net profit margin

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Net income (ttm)	US$ in thousands	16,897	-535,977	-690,876	-907,677	-1,115,218	-703,488	-716,225	-506,631	-356,555	-418,780	-486,116	-634,471	-703,886	-554,128	-600,514	-530,341	-655,924	-715,075	-620,267	-570,334
Revenue (ttm)	US$ in thousands	1,403,300	1,243,336	1,104,982	1,003,434	975,683	933,013	876,047	835,184	765,786	701,887	645,564	600,082	573,356	540,099	495,074	450,191	407,496	380,833	365,135	344,580
Net profit margin		1.20%	-43.11%	-62.52%	-90.46%	-114.30%	-75.40%	-81.76%	-60.66%	-46.56%	-59.66%	-75.30%	-105.73%	-122.77%	-102.60%	-121.30%	-117.80%	-160.96%	-187.77%	-169.87%	-165.52%

March 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $16,897K ÷ $1,403,300K
= 1.20%

The net profit margin of Sarepta Therapeutics Inc has shown significant fluctuations over the past few quarters. In the most recent period ending March 31, 2024, the company reported a net profit margin of 1.20%, indicating that about 1.20% of its revenues translated into profits. This marks a positive turn compared to the previous quarters, such as December 31, 2023, where the net profit margin was notably negative at -43.11%.

The trend of negative net profit margins seen in some previous quarters, like September 30, 2023, June 30, 2023, and March 31, 2023, is concerning as it suggests that the company was incurring losses exceeding its revenues during those periods. These periods saw net profit margins of -62.52%, -90.46%, and -114.30% respectively.

It is important to note that the company's profitability improved significantly in the latest quarter, but the overall trend over the past few years shows fluctuations with periods of substantial losses reflected in the negative net profit margins. Further analysis of Sarepta Therapeutics Inc's financial performance and strategies may be required to understand the factors driving these fluctuations in net profit margins.